Vaxcyte, Inc. (PCVX) earnings date
Feb 23, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | after close | 36 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | after close | 36 | 8-K |
| Q4 FY2025 | Tue, Feb 24, 2026 | after close | 55 | 8-K |
| Q3 FY2025 | Tue, Nov 4, 2025 | after close | 35 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | after close | 37 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | after close | 37 | 8-K |
| Q4 FY2024 | Tue, Feb 25, 2025 | after close | 56 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 Across All Ages Studied VAX-31 Adult Indication: Company Expects to Report Results from OPUS-2 and OPUS-3 Phase 3 Trials in First Half of 2027, Supporting Planned Biologics License Application Submission in First Half of 2028 VAX-31 Infant Indication: Topline Safety, Tolerabil" exhibit |
| Q3 FY2026 | "With OPUS-1 serving as the foundation of our planned Biologics License Application (BLA), we remain on track to announce results from the OPUS-2 and OPUS-3 Phase 3 trials in the first half of next year and, together with a manufacturing consistency study, we expect to submit a BLA in the first half of 2028." exhibit |
| Q3 FY2026 | "For the VAX-31 infant indication, we expect to announce topline data from the primary immunization series and booster dose of the ongoing Phase 2 study, either sequentially or together, by the end of the first half of 2027.”" exhibit |
| Q3 FY2026 | "OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027, Supporting Planned BLA Submission in First Half of 2028: The OPUS-2 and OPUS-3 Phase 3 trials, which are fully enrolled, are designed to generate a broad and robust safety, tolerability and immunogenicity dataset as part of the OPUS Phase 3 program evaluating VAX-31 for the prevention of IPD and pneumococcal pneumonia." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose of VAX-31 Infant Phase 2 Dose-Finding Study Expected Either Sequentially or Together by End of First Half of 2027 Company Initiated Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Cause" exhibit |
| Q2 FY2026 | ""We are on track to deliver the topline data from the OPUS-1 noninferiority trial in the fourth quarter of this year." exhibit |
| Q2 FY2026 | "Following, we expect to announce the results of the OPUS-2 and OPUS-3 trials in the first half of 2027, which along with a manufacturing consistency study, would enable our planned Biologics License Application (BLA) submission and potential U.S. commercial launch." "With $2.5 billion in cash, cash equivalents and investments as of June 30, 2026, we maintain a strong balance sheet and are well positioned to execute on our planned clinical, manufacturing and commercial-readiness milestones across our PCV development programs," said Andrew Guggenhime, President and Chief Financial Officer of Vax" exhibit |
| Q2 FY2026 | ""As we prepare for the Company’s next phase of growth, we continue to advance our early-stage pipeline, including VAX-A1, a prophylactic vaccine candidate designed to prevent disease caused by Group A Strep, now in a Phase 1 adult study, and VAX-XL, our preclinical, next-generation PCV candidate designed to provide the broadest coverage of any PCV currently in development." Key Second Quarter and Recent Highlights PCV Franchise Adult Indication: Enrollment Completed for Three VAX-31 Adult Phase 3 OPUS Trials; Topline Data from OPUS-1 Expected in Fourth Quarter 2026: All three ongoing VAX-31 Ph" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/PCVX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/PCVX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/PCVX/"><img src="https://veritasdata.dev/embed/PCVX.svg" alt="PCVX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/PCVX/)
Script
<script async src="https://veritasdata.dev/embed/PCVX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/PCVX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.